Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OFF plus best supportive care versus best supportive care alone in gemcitabine-refractory advanced pancreatic cancer
ISRCTN52780546Phase 3Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jan 2004
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, folinic acid and fluorouracil in pancreatic cancer (PC) (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoints: Overall survival and Progression-free survival. Started Jan 2004; status: completed.
02
Drugs
oxaliplatinfolinic acidfluorouracil
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ISRCTN52780546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN52780546.